AGENDA

Enclosure

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting

To protect commercial confidentiality, the morning session of four appraisals will be conducted in private. The final appraisal recommendations will be announced in public after the lunch break

5. Appraisal 1 - Full Submission (WPAS)
   Insulin degludec (Tresiba®) for the treatment of diabetes mellitus in adults

6. Appraisal 2 - Full Submission (WPAS)
   Velaglucerase alfa (VPRIV®) for long-term enzyme replacement therapy in patients with type 1 Gaucher disease

7. Appraisal 3 - Full Submission (PAS)
   Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

8. Appraisal 4 - Full Submission (PAS)
   Abiraterone acetate (Zytiga®) in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

The meeting will now open to the public (approx 2.00pm)
9. Chairman’s report (verbal update)


11. Feedback from AWPAG Meeting 12th March 2014

12. Appraisal 5 - Full Submission
    Imatinib (Glivec®) as adjuvant treatment, for up to 36 months, of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment

13. Appraisal 6 – Limited Submission
    Emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®) for antiretroviral treatment-experienced adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera

Date of next meeting:
Wednesday 16th July 2014 in Cardiff